A battle brews between Baupost Group and short investors drug firm Keryx
This Friday could be an eye-opener for the many investors betting against Boston-based Keryx Biopharmaceuticals. That’s when its biggest investor will reveal whether it’s standing firm or cutting its losses following months of share declines.
Boston-based Keryx (Nasdaq: KERX) has seen an increase in the volume of “short interest” — investors who profit from stock losses, rather than gains — over the past year as it’s launched its drug, Auryxia, for chronic kidney disease. Perhaps anticipating…
Source: bizjournals.com Health Care:Hospitals headlines - Category: Hospital Management Authors: Don Seiffert Source Type: news
More News: Chronic Kidney Disease | Health | Health Management | Hospital Management | Hospitals | Urology & Nephrology